nach oben

Quality of Life Research

Erschienen in:

01.09.2012

Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients

verfasst von: Eun-ju Kim, Su-Kyoung Ko, Hye-Young Kang

Erschienen in: Quality of Life Research | Ausgabe 7/2012

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To develop a mapping algorithm for a conversion of the EORTC QLQ-C30 and EORTC QLQ BR-23 into the EQ-5D-derived utilities in metastatic breast cancer (MBC) patients.

Methods

We enrolled 199 patients with MBC from four leading Korean hospitals in 2009. EQ-5D utility, cancer-specific (QLQ-C30) and breast cancer-specific quality of life data (QLQ-BR23) and selected clinical and demographic information were collected from the study participants. Ordinary least squares regression models were used to model the EQ-5D using QLQ-C30 and QLQ-BR23 scale scores. To select the best model specification, six different sets of explanatory variables were compared.

Result

Regression analysis with the multiitem scale scores of QLQ-C30 was the best-performing model, explaining for 48.7% of the observed EQ-5D variation. Its mean absolute error between the observed and predicted EQ-5D utilities (0.092) and relative prediction error (2.784%) was among the smallest. Also, this mapping model showed the least systematic errors according to disease severity.

Conclusions

The mapping algorithms developed have good predictive validity, and therefore, they enable researchers to translate cancer-specific health-related quality of life measures to the preference-adjusted health status of MBC patients.

Nur mit Berechtigung zugänglich

Kontodimopoulos, N., Aletras, V. H., Paliouras, D., & Niakas, D. (2009). Mapping the cancer-specific EORTC QLQ-C30 to the preference-based EQ-5D, SF-6D, and 15 D instruments. Value in Health, 12(8), 1151–1157.PubMedCrossRef

Patrick, D. L., & Deyo, R. A. (1989). Generic and disease-specific measures in assessing health status and quality of life. Medical Care, 27(Supp l), S217–S232.PubMedCrossRef

Rivero-Arias, O., Quellet, M., Gray, A., Wolstenhome, J., Rothwell, P. M., & Luengo-Fernandez, R. (2009). Mapping the modified rankin scale (mRS) measurement into the generic EuroQol (EQ-5D) health outcome. Medical Decision Making, 30(3), 341–354.PubMedCrossRef

Cheung, Y. B., Tan, L. C. S., Lau, P. N., Au, W. L., & Luo, N. (2008). Mapping the eight-item Parkinson’s Disease Questionnaire (PDQ-8) to the EQ-5D utility index. Quality of Life Research, 17, 1173–1181.PubMedCrossRef

Bottomley, A., & Aaronson, N. K. (2007). International perspective on health-related quality-of-life research in cancer clinical trials: The European Organization for Research and Treatment of Cancer experience. Journal of Clinical Oncology, 25(32), 5082–5086.PubMedCrossRef

Aaronson, N. K., Ahmedzai, S., Bergman, B., et al. (1993). The European organization for research and treatment of cancer QLQ C-30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute, 85(6), 365–376.PubMedCrossRef

McKenzie, L., & Pol, M. (2009). Mapping the EORTC QLQ C-30 onto the EQ-5D instrument: The potential to estimate QALYs without generic preference data. Value in Health, 12(1), 167–171.PubMedCrossRef

Wu, E. Q., Mulani, P., Farrell, M. H., & Sleep, D. (2007). Mapping FACT-P and EORTC QLQ-C30 to patient health status measured by EQ-5D in metastatic hormone-refractory prostate cancer patients. Value in Health, 10(5), 408–414.PubMedCrossRef

Crott, R., & Briggs, A. (2010). Mapping the QLQ-C30 quality of life cancer questionnaire to EQ-5D patient preferences. The European Journal of Health Economics, 11(4), 427–434.PubMedCrossRef

10.

Korea National Cancer Information Center. (2010). Prevalence of cancer. cited August 28, 2010, from URL http://www.cancer.go.kr/cms/statistics/stat/1373001_1611.html.

11.

Health Insurance Review and Assessment Services. (2006). Korean pharmaceutical economic evaluation guidelines. Cited December 25, 2010, from URL http://www.ispor.org/PEguidelines/source/Korean_PE_Guidelines_Korean_Version.pdf.

12.

Fayers, P. M., Aaronson, N. K., Bjordal, K., Curan, D., & Groenvold, M. (1999). On behalf of EORTC quality of life study group. EORTC QLQ-C30 scoring manual (2nd ed.). Brussels: EORTC.

13.

Sprangers, M. A. G., Groenvold, M., Arraras, J. I., et al. (1996). the EORTC breast cancer-specific quality-of-life questionnaire module: First results from a three-country field study. Journal of Clinical Oncology, 14(10), 2756–2768.PubMed

14.

The EuroQol Group. EQ-5D. Cited December 25, 2010, from URL http://www.euroqol.org.

15.

Lee, Y. K., Nam, H. S., Chuang, L. H., et al. (2009). South Korean time trade-off values for EQ-5D health states: Modeling with observed values for 101 health states. Value in Health, 12(8), 1187–1193.PubMedCrossRef

16.

Borras, J. M., Sanchez-Hernandez, A., Navarro, M., et al. (2001). Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: A randomized controlled trial. British Medical Journal, 322, 1–5.CrossRef

17.

World Health Organization. (1980). WHO handbook for reporting results of cancer treatment. Neoplasma, 20, 37–46.

18.

Dakin, H., Petrou, S., Haggard, M., Benge, S., & Williamson, I. (2010). Mapping analyses to estimate health utilities based on responses to the OM8–30 otitis media questionnaire. Quality of Life Research, 19(1), 65–80.PubMedCrossRef

19.

Versteegh, M. M., Rowen, D., Brazier, J. B., & Stolk, E. A. (2010). Mapping onto EQ-5 D for patients in poor health. Health and Quality of Life Outcomes, 8, 141.PubMedCrossRef

20.

Brazier, J. E., Yang, Y., Tsuchiya, A., & Rowen, D. L. (2009). A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. European Journal of Health Economics, 2010(11), 215–225.

21.

Rowen, D., Brazier, J., & Roberts, J. (2009). Mapping SF-36 onto the EQ-5 D index: How reliable is the relationship? Health and Quality of Life Outcomes, 7, 27.PubMedCrossRef

22.

Sauerland, S., Weiner, S., Dolezalova, K., Angrisani, L., Noguera, C. M., Garcia-Caballero, M., et al. (2009). Mapping utility scores from a disease-specific quality-of-life measure in Bariatric surgery patients. Value in Health, 12(2), 364–370.PubMedCrossRef

23.

Vittinghoff, E., Shiboski, S. C., Glidden, D. V., McCulloch, C. E. (2005). Regression methods in biostatistics: Linear, logistic, survival, and repeated measures models (Chap. 5, pp. 147–148). New York: Springer Science+Business Media, Inc.

24.

SAS/STAT(R) 9.2 (2009). User’s Guide (2nd ed.), (Chap. 4, pp. 98). Cary, North Carolina, USA: SAS Institute Inc.

25.

Korea Center for Disease Control and Prevention. (2007). The Korea national health and nutrition examination survey (KNHANES IV). Seoul: Korea Ministry of Health, Welfare, and Family Affairs, p. 290.

Titel: Mapping the cancer-specific EORTC QLQ-C30 and EORTC QLQ-BR23 to the generic EQ-5D in metastatic breast cancer patients
verfasst von: Eun-ju Kim
Su-Kyoung Ko
Hye-Young Kang
Publikationsdatum: 01.09.2012
Verlag: Springer Netherlands
Erschienen in: Quality of Life Research / Ausgabe 7/2012
Print ISSN: 0962-9343
Elektronische ISSN: 1573-2649
DOI: https://doi.org/10.1007/s11136-011-0037-y

Springer Medizin

Abstract

Purpose

Methods

Result

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2012

Validation of the Swedish translation of the general self-efficacy scale

Longitudinal changes in social functioning in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon β-1a: results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study (II)

The prevalence of hearing impairment and its burden on the quality of life among adults with Medicare Supplement Insurance

The association between cumulative adversity and mental health: considering dose and primary focus of adversity

The internal responsiveness of the Oral Health Impact Profile-14 to detect differences in clinical parameters related to surgical third molar removal

Erratum to: Psychometric evaluation of the Cystic Fibrosis Questionnaire-Revised in a national, US sample